Maternal and neonatal outcomes after benzodiazepine and
benzodiazepine agonist exposure during pregnancy in women with mental
disorders
Hennique Knobbe1, Elvera A. Damer2,
Mireille A. Edens3, Bas S.W.A. Nij
Bijvank4, Marieke A.C. Hemels5,
Peter G.J. ter Horst1, 6
1: Isala, Department of Clinical Pharmacy,
E=hennique@hotmail.com
; 2: Isala, Department of Psychiatry, E=e.a.damer@isala.nl; 3: Isala,
Isala Academie,
E=m.a.edens@isala.nl ;
4: Isala, Department of Gynecology and Obstetrics, E=
s.w.a.nijbijvank@isala.nl
; 5: Isala, Department of Neonatology,
E=m.a.c.hemels@isala.nl
; 6: Corresponding author: Dr. P.G.J. ter Horst, Ph.D., PharmD, hospital
pharmacist. Isala; department of Clinical Pharmacy; dr van Heesweg 2;
8025 AB Zwolle, The Netherlands; T= 0031 38 424 2469;
E=p.g.j.ter.horst@isala.nl